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Lentigo maligna (LM) is an in situ form of melanoma 
which can progress into invasive lentigo maligna mela­
noma (LMM). Variations in the pigmentation and thus 
visibility of the tumour make assessment of lesion bor­
ders challenging. We tested hyperspectral imaging sys­
tem (HIS) in in vivo preoperative delineation of LM and 
LMM margins. We compared lesion margins delineated 
by HIS with those estimated clinically, and confirmed 
histologically. A total of 14 LMs and 5 LMMs in 19 pa­
tients were included. HIS analysis matched the histo­
pathological analysis in 18/19 (94.7%) cases while in 1/19 
(5.3%) cases HIS showed lesion extension not confirmed 
by histopathology (false positives). Compared to clinical 
examination, HIS defined lesion borders more accura­
tely in 10/19 (52.6%) of cases (wider, n = 7 or smaller, 
n = 3) while in 8/19 (42.1%) cases lesion borders were the 
same as delineated clinically as confirmed histologically. 
Thus, HIS is useful for the detection of subclinical LM/
LMM borders. Key words: lentigo maligna; lentigo ma-
ligna melanoma; tumour margin assessment; hyperspec-
tral imaging.
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Lentigo maligna (LM) is an in situ form of melanoma 
where the neoplastic cells are confined to the epidermis 
and lack dermal invasion. LM is the most prevalent in 
situ subtype (79–83%) of melanoma. If untreated LM 
may progress into invasive lentigo maligna melanoma 
(LMM). The incidence of LM and LMM is constantly 
increasing over the other melanoma subtypes (1, 2). Early 
and efficient surgical removal is the method of choice in 
the treatment of LM and LMM.
Assessment of the borders of LM and LMM is chal-
lenging both clinically and histologically. Lesions can 
extend several cm beyond the clinically estimated 
margins (3). In clinical practice Wood’s light (320–400 
nm) is widely used to help the delineation of the tumour 
margins. Melanin absorbs most of the UV radiation skin 
is exposed to. Thus, Wood’s light increases the contrast 
between healthy skin and areas presenting even minor 
increases in epidermal melanin pigmentation (4). How-
ever, the pigment content may not be increased in all 
areas of LM growth.
We have earlier shown that a novel hyperspectral ima-
ging system (HIS) efficiently detects areas of subclinical 
skin field cancerisation (5). Hyperspectral imaging 
combines traditional spectroscopy and imaging techni-
ques by producing 3 dimensional data cubes, referred 
as hyperspectral images, where in addition to spatial 
(x, y location) information, image contains a spectral 
graph (z intensity) for each pixel (6). Thus, hyperspec-
tral image consists of a stack of images, of which each 
image is taken at different narrow wavelength and each 
pixel in the image has its own spectral signature (Fig 1). 
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Fig. 1. Hyperspectral imaging process and data analysis. Hyperspectral image (cube) consists of overlapping images, of which each is taken at different 
wavelength. Each pixel in the hyperspectral image has its own spectral signature. Mathematical algorithms (VCA, FVA) are used to separate the spectra 
(endmembers) of benign and malignant tissue. The abundance images represent the areas of lesional and healthy skin.
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Different biological tissues can be identified from their 
unique spectral signatures reflecting their biochemical 
characteristics (6–8). This pilot study aimed to test the 
feasibility of the HIS in delineation of the margins of 




The study protocol followed the Declaration of Helsinki and 
was approved by the local ethics committee. All volunteering 
patients provided their written informed consent. The patients 
were recruited from those remitted to the Department of Der-
matology for their suspected LMs. 
Nineteen patients, 7 women and 12 men, with clinically 
suspect LM or LMM located on their faces or scalps were 
included in the study. The patients’ mean age was 77.9 (range 
67–97 years). Three patients displayed skin photo-type I, 8 
photo-type II, and 8 photo-type III (9). Nine patients out of 
19 had earlier been treated for a non-melanoma skin cancer or 
premalignant skin lesions (basal cell carcinoma n = 2, actinic 
keratosis n = 2 or both n = 5). None of the patients had earlier 
been treated for melanoma. 
Clinical assessment of the lesion borders using digital imaging 
and Wood’s light examination
Prior to the imaging processes lesions were evaluated using 
dermatoscopy (Dermlite® DL3). Clinical assessment of the lesion 
borders was carried out using Wood’s light examination (Bur-
ton®) and digital photography (Canon Ixus 130, 14.1 megapixel). 
Hyperspectral imaging system and image analysis
All 19 lesions were imaged prior to surgical removal using HIS. 
The used handheld HIS was developed for the study at the VTT 
Technical Research Centre of Finland and University of Jyväskylä, 
Finland. This prototype imaging system consisted of a hyperspec-
tral imager (500–850 nm) (10, 11), external light source of visible 
and infrared light, fibre optic ring light and a holder for the imager 
and the ring light. The field of view was 12 cm2. HIS acquired 
the diffuse reflectance of the detected skin areas rapidly in a few 
seconds. The acquired hyperspectral data cube was analysed using 
an assumption of the linear mixture model (vertex component 
analysis, VCA and filter vector algorithm FVA) (12–14) to achieve 
pure spectra (endmembers) of LM/LMM and healthy skin (Fig. 
S11) and to produce abundance maps for delineation of the lesion 
borders (Fig. 2, Fig. S21). The hyperspectral imager and the ana-
lysing process are shown in Fig. 1, and detailed in Appendix S11.
Histopathological sampling
The lesions of 5/19 patients were biopsied before recruiting to 
the study and excised immediately after the imaging processes. 
The edges of the specimens were marked with orienting sutures, 
and inked for orientation. To help mapping the findings for 14/19 
patients, we took targeted 3 mm punch biopsies (2–4 per patient) 
from the middle and from lesions borders, defined using the HIS, 
and afterwards the lesions were completely excised with wide 
excision margins. The biopsy sites and excision margins were 
marked and photographed. An experienced dermatopathologist 
(LJ) examined the samples without any background information. 
RESULTS
The comparative analyses included a total of 14 LMs 
and 5 LMMs located on the face and scalp (nose n = 1, 
ear n = 4, eyelid n = 2, forehead n = 2 and on the cheek 
area n = 10) of 19 patients. The invasion depth (Bres-
low thickness) of the LMMs varied between 0.5 and 
1.25 mm. The mean lesion area was 2.4 cm2 (range 
1.6–7.6 cm2).
In the delineation of LM or LMM margins, HIS analysis 
matched the histopathological analysis in 18/19 (94.7%) 
1http://www.medicaljournals.se/acta/content/?doi=10.2340/00015555-2010
Fig. 2. Lentigo maligna melanoma on lower eyelid (patient 
19). (a) Lesion in Wood’s light, (b) Clinical wide excision 
margins, (c) Hyperspectral abundance map showing 
subclinical lesion extension (arrows), (d) Histological image 
(HE-staining magnification × 20) of the squared are from 
Fig 2 c. Atypical melanocytic nests in dermo-epidermal 
junction and solar elastosis. The wide excision verified the 
HIS results of subclinical lesion extension.
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cases while in 1/19 (5.3%) cases HIS showed lesion 
extension not confirmed by histopathology (false positi-
ves). In 10/19 (52.6%) of the cases lesion margins were 
delineated more accurately (wider, n = 7 or smaller, n = 3) 
by HIS than by clinical examination with Wood’s light, as 
confirmed by histopathological analysis (Fig 2, Fig S21). 
In 8/19 (42.1%) cases the lesion margins were equally 
delineated by HIS and clinical examination, as confirmed 
by histopathology. No false negatives were detected when 
comparing HIS detection with histopathology.
In the false positive case an actinic keratosis and 
benign lentigo was present histologically on the LM 
borders which complicated the interpretation of the 
HIS image.
 The lesions were operated in accordance with current 
standards by removing LMs with 5 mm clinical margins 
and LMMs with 10 mm margins if anatomically pos-
sible (15). As this was a pilot study, the margins given 
by HIS were not used in the excisions. After receiving 
the results from the histopathological analyses, 3/14 of 
the LM lesions and 2/5 LMM lesions needed re-excision 
because of the subclinical extension of the lesion bor-
ders. If the excision borders had been selected on the 
basis of the HIS analysis, 5 re-excisions could have 
been avoided (Table I).
DISCUSSION
This study indicates that the HIS is capable of detecting 
the subclinical borders of LM and LMM. Importantly, 
in over 50% of the cases, the lesion margins were as-
sessed more accurately by using the HIS than with 
the clinical methods. The advantages of HIS include 
a handheld imager with a large field of view (12 cm2) 
and a quick imaging process. All studied skin areas 
including the nose and ears were suitable for imaging 
with the HIS and fitted the field of view. 
The lesions were removed with margins determined 
after delineating the tumour visually using Wood’s light. 
Three LM patients and 2 LMM patients needed re-ex-
cision because of the histologically verified subclinical 
extension of the lesions. Interestingly, if the patients 
had initially been operated on using margins given by 
HIS, the re-excisions could have been avoided. HIS also 
seems to be inversely useful, since clinical assessments 
delineated 3 LM lesions incorrectly larger than depicted 
using HIS and confirmed by histopathology.
Discrimination of LM from sun-damaged skin at the 
periphery of lesions may also be challenging histologi-
cally (3). The cytological atypia in LM may vary and 
be subtle. The diffuse melanocytic overgrowth of sun-
damaged skin and the presence of benign melanocytes 
along the hair follicles make it challenging to assess 
the peripheral margins of LM. Immunohistochemistry, 
for e.g. MART-1, is sometimes used to identify LM. 
However, also normal, chronically sun-exposed skin 
has a high number of MART-1 positive melanocytes 
(16, 17). In one case in our study, benign lentigines 
and subclinical AK surrounding the LM made it dif-
ficult to correctly interpret the HIS image and led to a 
false positive interpretation. These lesions might have 
complicated the histopathological analysis as well.
Wood’s light turned out to be of only marginal help 
in assessing the margins of LMs. Especially in cases 
where also benign lentigines were present, the delinea-
tion of LM with Wood’s light was complicated. Since 
both melanin and haemoglobin strongly absorb visible 
and UV light (4), a future developmental aspect could 
be to integrate a UV light source to HIS to improve 
visualisation of the pigmentation.
There are several commercially available devices 
for skin cancer detection and a magnitude of research 
in the field (18, 19). As far as we know there are no 
commercial applications of a HIS. Previously, a few 
techniques have been used to assess surgical margins 
includings: dermatoscopy, confocal microscopy and 
optical coherence tomography. 
Dermatoscopy (epiluminescence microscopy) helps 
in defining the LM borders, but requires an experienced 
dermatoscopist (20). LM on the face do not show the 
classical dermoscopic features found on the other parts 
of the skin, which makes their observation more chal-
lenging (21). In this study dermatoscopy was used as a 
diagnostic aid, but not for the delineation of the lesions.
Confocal microscopy has shown potential in evalua-
ting pigmented skin lesions and their margins (22). The 
device detects to depths of 300 µm, i.e. to the papillary 
Table I. Lesion characteristics in hyperspectral images (HIS) 














1 In situ Wider – – +
2 In situ Wider – – +
7 In situ Wider – – +
16 1.25 mm Wider – – +
19 0.50 mm Wider – – +
6 In situ Widerd – – –
17 0.75 mm Widerd – – –
4 In situ Smaller – – –
8 In situ Smaller – – –
13 In situ Smaller – – –
3 In situ – Identical – –
5 In situ – Identical – –
9 In situ – Identical – –
11 In situ – Identical – –
14 In situ – Identical – –
15 0.70 mm – Identical – –
18 0.70 mm – Identical – –
10 In situ – Identical – –
12 In situ – +Wider –
aHIS shows lesion margins more accurately compared to clinical evaluation 
as confirmed histologically. bLesion borders similarly detected clinically, by 
HIS and histology. cHIS shows lesion wider than histologically confirmed. 
dOnly minor subclinical extension, no need for re-excision.
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dermis. The limitation in confocal microscopy is a small 
field of view (FOV 8 × 8 mm mosaic composite ima-
ges) leading to several slow imaging sessions for each 
lesion. The method lacks any objective analysis and 
the assessment of one FOV area requires at least 5 min 
for an expert which makes the method slow compared 
to HIS (23, 24).
Optical coherence tomography (OCT), has shown 
potential in delineating the borders of non-melanocytic 
skin malignancies (25). As far as we know there are no 
studies of the delineation of pigmented lesions using 
OCT. The device provides high-resolution cross-sectio-
nal images at greater depths (1.5–2 mm) than confocal 
microscopy. The FOV is small (6 × 6 mm), thus making 
the imaging process slower than in HIS. The analysis 
remains subjective.
We have earlier shown that the HIS is useful in the 
detection of skin field cancerisation (5). In the present 
study HIS showed its potential in the detection of the 
subclinical borders of LM and LMM. By detecting ac-
curate margins for the lesions, cumbersome re-excisions 
could be avoided. In addition, HIS could also be used 
to spare facial tissue in cases where lesion borders are 
smaller than shown by clinical assessments. HIS can 
offer clinicians a practical tool for a non-invasive de-
lineation of tumour borders. As this was a pilot study 
with limited cases further studies are warranted to 
validate the results. 
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